Vitamin D protects against ulcerative colitis by triggering colon cells to produce cathelicidin, an antimicrobial peptide that fights bacteria and reduces gut inflammation.
Cathelicidin links vitamin D to UC protectionHigher serum cathelicidin was associated with decreased risk of histologic inflammation and clinical relapse in UC patients, and vitamin D directly induced cathelicidin production in human colon cells.
What the researchers found
Vitamin D's protective effects in ulcerative colitis (UC) appear to work through cathelicidin, an antimicrobial peptide. In UC patients, higher vitamin D levels correlated with higher cathelicidin levels in both blood and colon tissue, and higher serum cathelicidin was associated with decreased risk of histologic inflammation and clinical relapse. In lab experiments, vitamin D treatment of human colon cells induced cathelicidin production and the anti-inflammatory cytokine IL-10, suppressed the pro-inflammatory cytokine TNF-α, and killed E. coli bacteria — an antimicrobial effect that disappeared when cathelicidin was knocked down. In mice, rectal cathelicidin administration reduced the severity of chemically induced colitis.
Why it matters
Vitamin D supplementation has long been associated with better outcomes in inflammatory bowel disease, but the mechanism was unclear. This study identifies cathelicidin as a key mediator — vitamin D triggers colon cells to produce this antimicrobial peptide, which then fights harmful bacteria and reduces inflammation. This opens the possibility of directly targeting the vitamin D-cathelicidin pathway as a treatment for UC.
How the study worked
A multi-part study: (1) Measured serum and colonic cathelicidin levels in UC patients and correlated them with clinical outcomes. (2) Treated human colon epithelial cells with active vitamin D and measured cathelicidin, cytokines (IL-10, TNF-α), and antimicrobial activity against E. coli, with siRNA knockdown to confirm cathelicidin's role. (3) Administered intrarectal cathelicidin to mice with DSS-induced colitis and assessed disease severity and gut microbiota changes.
Who was studied
Ulcerative colitis patients (human observational), human colon epithelial cells (in vitro), and C57BL/6 mice with DSS-induced colitis
What this study cannot tell us
The correlation between cathelicidin and reduced inflammation in UC patients was not independent of vitamin D levels or baseline inflammation, making it difficult to separate cathelicidin's independent effect. The mouse model used chemically induced colitis, which differs from human UC. Intrarectal cathelicidin reduced colitis severity but did not reverse the changes in gut microbiota composition caused by colitis.
How to read the evidence
This study combines human observational data, cell culture experiments, and a mouse model, providing moderate evidence. The human data shows correlation but not independent causation, and the animal model adds mechanistic support but requires validation in human clinical trials.
When this study was published
Published in 2020, this study is relatively recent and represents current understanding of the vitamin D-cathelicidin axis in IBD. The pathway it identifies remains an active area of therapeutic research.
The bigger picture
This study connects two well-known areas of research — vitamin D in IBD and antimicrobial peptides in gut defense — by showing cathelicidin is the link between them. It adds to growing evidence that the innate immune system's antimicrobial peptides play a central role in maintaining gut health, and suggests that boosting cathelicidin production (whether through vitamin D or directly) could become a therapeutic strategy for inflammatory bowel disease.
Questions still open
- Could direct cathelicidin supplementation (rectal or oral) be developed as a standalone therapy for ulcerative colitis?
- Why didn't cathelicidin restore the disrupted gut microbiota in mice, even though it reduced colitis severity?
- What vitamin D dose is needed to meaningfully increase colonic cathelicidin production in UC patients?
Common questions
How does vitamin D help protect against ulcerative colitis?
Could cathelicidin become a direct treatment for ulcerative colitis?
Read the original research
Cathelicidin Mediates a Protective Role of Vitamin D in Ulcerative Colitis and Human Colonic Epithelial Cells.
Inflammatory bowel diseases, 26(6), 885-897
Citation
Gubatan, John; Mehigan, Gillian A; Villegas, Fernando; Mitsuhashi, Shuji; Longhi, Maria Serena; Malvar, Grace; Csizmadia, Eva; Robson, Simon; Moss, Alan C. (2020). Cathelicidin Mediates a Protective Role of Vitamin D in Ulcerative Colitis and Human Colonic Epithelial Cells.. Inflammatory bowel diseases, 26(6), 885-897. https://doi.org/10.1093/ibd/izz330